Condition
Severe Symptomatic Calcified Native Aortic Valve Stenosis
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Tavr
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT02255851Completed
Sentinel(TM) Post-Market Registry
NCT02214277Not ApplicableCompletedPrimary
Cerebral Protection in Transcatheter Aortic Valve Replacement
Showing all 2 trials
Research Network
Common Treatments
- Tavr1
- Cerebral Protection Systemthe Sentinel System With Tavr1
- Sentinel Cerebral Protection System1
Active Sponsors
- Claret Medical2
Top Investigators
The Cleveland Clinic
Elisabeth-Krankenhaus Essen GmbH, Essen, Germany
Columbia University
Related Conditions
- Transcatheter Aortic Valve Replacement1